

Combined Functional Electrical and Transcranial Direct Current Stimulation for Foot Drop: A Case Series

Sylvester Carter^a, Gregory Thielman^{b, c}

Abstract

Stroke is a leading cause of severe long-term disability, and foot drop is a common post-stroke gait impairment that may reduce toe clearance, increasing the risk of toe contacts and, in turn, trip-related falls. This case series evaluated the novel combination of transcranial direct current stimulation (tDCS), functional electrical stimulation (FES) to the tibialis anterior, and physical therapy training to improve minimum toe clearance (MTC) in individuals with chronic stroke. The rationale for this combined approach was that tDCS may prime the motor cortex and enhance neuroplastic responsiveness, while FES provides task-specific peripheral stimulation to the dorsiflexors during gait-related training, potentially increasing MTC and minimizing toe drag. Four individuals with chronic stroke participated in an 8-week treatment program with sessions twice a week. Assessments were conducted at baseline, 4 weeks, and 8 weeks. Participant 1 started with tDCS alone for 4 weeks, then added FES for the remaining 4 weeks. Participant 2 began with FES for the first 4 weeks, and tDCS was added for the remaining 4 weeks. Participants 3 and 4 received both tDCS and FES throughout the entire 8-week program. Participants 1 (58-year-old female) and 4 (42-year-old male) showed no active ankle dorsiflexion at baseline, while participants 2 (66-year-old male) and 3 (36-year-old male) had a grade of 2 out of 5 for ankle dorsiflexion strength at baseline. Toe clearance and functional outcomes were collected at each assessment. Participants 1 and 4 demonstrated no meaningful change in MTC, whereas participants 2 and 3 both showed modest improvements. Among these responders, MTC increased by an average of 0.63 cm. These findings suggest that combining cortical neuromodulation with localized FES and physical therapy may improve toe clearance in select individuals with chronic stroke. However, because tibialis anterior activation was not directly measured, it remains unclear whether the observed changes were due to improved dorsiflexor activation or other compensatory gait strategies.

Keywords: Falls; Foot drop; Minimum toe clearance; Functional electrical stimulation; Case series; Transcranial direct current stimulation; Stroke

Introduction

Approximately 795,000 people experience a stroke in the United States annually [1]. Foot drop is one of the most common disabilities experienced by stroke survivors, affecting between 20% and 30% of individuals [2, 3]. The consequences of foot drop include walking speed reductions [4], instability during walking [5], and increased risk of toe contacts due to a plantarflexed foot [6], all of which may increase fall risk [6–14]. In fact, in persons more than 1 year after a stroke, 36% experienced a fall within the previous year compared to 24% for age- and gender-matched controls [15]. The consequences of falls can include cuts and bruises, fractures, fear, a high caregiver burden, increased health services utilization, impaired quality of life, and death [16–18].

Minimum toe clearance (MTC) has been evaluated as a means of assessing the risk of trip-related falls [19–21]. Interest in this variable arose because foot drop increases ankle plantarflexion [22, 23], which limits swing-phase limb shortening [24–26], bringing the foot closer to the ground, increasing the risk of trip-related falls [6, 21, 27, 28]. Data from community-dwelling individuals with stroke show that 7% of falls and 22% of near falls are linked to difficulty clearing the affected limb, especially during the swing phase for near falls (19.4%) [29, 30]. Additionally, ankle plantarflexion at toe-off is approximately 1° greater during trip steps than during non-trip steps in individuals with chronic stroke [25].

Methods to address foot drop include ankle-foot orthoses (AFOs), surgical options, medical approaches, and functional electrical stimulation (FES), with no single best treatment identified [31]. Many methods have limited patient acceptance and high cost [31]. Among these, FES has the highest-quality evidence supporting its effectiveness, despite the small sample sizes of existing studies [31]. FES has been shown to improve walking speed, active dorsiflexion, balance, and daily activities, especially when combined with physical therapy training (PTT) [32, 33]. The hypothesized mechanisms underlying these improvements include increased muscle strength, improved joint flexibility, and cortical reorganization facilitated by volitional intent during stimulation [34]. However, one study found that

Manuscript submitted March 26, 2026, accepted June 22, 2026
Published online July 28, 2026

^aDepartment of Physical Therapy, Saint Joseph's University, Philadelphia, PA, USA

^bPatricia Leahy Movement Science Lab, Saint Joseph's University School of Health Professions, Philadelphia, PA, USA

^cCorresponding Author: Gregory Thielman, Patricia Leahy Movement Science Lab, Saint Joseph's University School of Health Professions, Philadelphia, PA, USA. Email: gthielman@sju.edu

doi: <https://doi.org/10.14740/jmc5333>
Journal of Medical Cases
1923-4155 (print), 1923-4163 (online)

Table 1. Patient Characteristics

Subject Number	Year of stroke	Affected side (L/R)	Ethnicity	Age (years)	Sex (M/F)	Weight (kg)	Height (m)	Past medical history
1	2010	L	Black/African American	58	F	68.04	1.75	Bowel and bladder irregularities, allergies, vascular clots
2	2007	L	Black/African American	66	M	105.91	1.69	Hypertension, diabetes
3	2020	L	Black/African American	36	M	68.49	1.69	Nerve disease/disorder, speech/communication deficits, paresthesia
4	2022	R	Black/African American	42	M	92.99	1.68	

L: left; R: right; M: male; F: female; m: meters; kg: kilograms.

after 42 weeks of FES, 32% of participants did not demonstrate a clinically meaningful improvement in gait speed, and 45% did not demonstrate a meaningful improvement in functional gait ability [3]. These findings highlight the need for adjunct therapies to enhance neuromuscular responses.

Transcranial direct current stimulation (tDCS) shows promise for reducing fall risk in persons post-stroke (PPS), despite limited research [35]. This non-invasive method increases cortical excitability with anodal stimulation and decreases it with cathodal stimulation [36]. Additionally, tDCS can induce neuroplastic changes in the motor cortex and enhance motor performance through “priming,” which may help balance transcallosal inhibition between hemispheres by increasing excitability in the ipsilesional hemisphere and decreasing excitability in the contralesional hemisphere [37]. Although tDCS lacks specificity for the lower limb because the lower-limb representation is located on the medial aspect of the motor cortex, it has been linked to reduced fall risk and improved lower-limb function in PPS [38]. Improvements have also been observed on tests such as the 6-min walk test and Tinetti’s performance-oriented mobility assessment, as well as in specific gait metrics, including gait speed and temporospatial measures [39, 40]. Additionally, anodal stimulation can enhance excitability in corticospinal projections to the tibialis anterior muscle, with effects lasting up to 60 min [41].

Evidence from animal studies suggests that pairing peripheral nerve stimulation (e.g., FES) with cortical stimulation (e.g., tDCS) may offer additional benefits [37]. However, results from human studies are mixed [42, 43]. One study found that FES combined with tDCS improved upper-limb function in PPS [42], whereas another found no significant effect on tibialis anterior muscle activity or static balance when FES was applied in isolation rather than during physical therapy [43]. This distinction is important because FES combined with physical therapy appears to yield better outcomes [32]. Therefore, this case series aimed to assess whether combining FES and tDCS during a physical therapy session could reduce foot drop by improving toe clearance and ankle dorsiflexion in PPS.

Case Report

Investigations

Table 1 presents the demographic information of each partici-

pant. This case series investigation received expedited IRB approval prior to enrollment of the reported participants. Participant 1, a 58-year-old female, had a right-sided cerebrovascular accident (CVA) that resulted in left lower limb weakness 13 years before the intervention. The participant ambulated without an AFO and could not produce active dorsiflexion outside of a synergistic flexion pattern with excessive ankle inversion on the affected left side. Neither participant 2 (a 66-year-old male) nor 3 (a 36-year-old male) ambulated in the community with their AFOs, but could produce active dorsiflexion, with a manual muscle test strength of grade 2. Participant 4 (a 42-year-old male) ambulated using a hinged AFO with a dorsiflexion stop and could not produce active dorsiflexion.

Diagnoses

Outcome measures included kinematic motion capture, functional gait assessment (FGA), Activity-specific Balance Confidence Scale (ABC), Walk-12, and the Stroke Impact Scale.

For the motion capture, participants were fitted with a modified Cleveland Clinic marker set, in which four clusters of four markers were attached to the thighs and shanks, and wand-mounted markers were also attached bilaterally to the anterior superior iliac spines (ASIS) and the sacrum. Additionally, seven 14 mm reflective markers were attached to the shoe at the upper ridge of the posterior surface of the calcaneus, sustentaculum tali, and lateral aspect of the calcaneus (peroneal tubercle), and the heads of the first, second, and fifth metatarsal (MET) and at the tip of the shoe/second digit if barefooted. In Visual 3D (C-Motion, Maryland, USA), a single-segment foot was built with the first and fifth MET head markers and a virtual ankle joint (constructed from virtual markers of the lateral and medial malleoli) using the calibrated anatomical system technique (CAST) described by Cappozzo et al [44, 45].

During each testing session, all participants completed 25 walking trials, each at a self-selected normal walking speed. All participants walked without an AFO, either barefoot (participant 1) or in their shoes (participants 2, 3, and 4). Eight infrared cameras (Bonita 10 cameras; VICON Nexus software v. 2.15.0; Oxford, UK) recorded at 100 Hz and captured the marker trajectories in the central 7 m of a 13-m walkway. Participants began walking at least 2.5 m before the cameras’ collection volume to reach steady-state walking in the volume.




Figure 1. The location of virtual points on the shoe (a) and barefoot (b).

Data analysis

The marker data were initially processed using Vicon Nexus 15 software (Oxford, UK), during which marker labeling and gap filling were performed. In Visual 3D (C-Motion, Maryland, USA), marker trajectories were filtered with a zero-phase shift, low-pass, fourth-order Butterworth filter with a cutoff frequency of 6 Hz. To determine the joint angles, 3D marker trajectories were processed with Visual 3D pipelines using the Cardan rotation sequence X-Y-Z to derive joint angle data. For flexion-extension movements in the sagittal plane, rotations were characterized around the mediolateral (X) axis. Hip adduction and abduction movements were negated on the left limb, allowing for interpretation similar to the right limb. The gait events, heel strike, and toe-off were identified using kinematic data with an automated program in Visual 3D [46]. All events were verified by visual inspection. Next, Visual 3D's metric compute temporal distance command was used to calculate temporal distance gait parameters from the gait events.

Visual 3D's (C-Motion, Maryland, USA) Landmark function was used to define the virtual points. A digitizing pointer was used during the static calibration trial to create the virtual markers (landmarks) and to establish their relationship to the local coordinate system of the tracking cluster (first and fifth MET and shoe tip/second digit-tip markers) [47–50]. The virtual points comprised a point on the tip of the shoe and four other virtual points on the shoe's medial, anterior, and lateral aspects, except when barefoot, when the tips of each digit comprised the virtual points (Fig. 1). These points are positioned to characterize the front of the shoe because this is the part that may contact the floor in the mid-swing phase of the gait cycle and result in a trip-related fall [51].

Treatment

The interventional procedures were designed to provide pre-

liminary, individual level data on whether adding tDCS or FES would yield further improvements beyond either modality alone. Since either intervention may affect MTC independently, performing tDCS and FES together at the outset would have precluded our ability to determine whether adding the other modality was associated with improvements beyond either modality alone. Therefore, for this exploratory evaluation, participant 1 began the first 4 weeks with tDCS alone, then added FES at week 4. This sequence allowed us to examine whether the addition of FES was associated with further change beyond that observed during the initial tDCS only phase. Conversely, participant 2 began the first 4 weeks with FES alone and added tDCS at week 4, allowing us to examine whether the addition of tDCS was associated with further change beyond that observed during the initial FES only phase. Next, we examined whether the combined treatment of tDCS and FES throughout the entire 8-week intervention period was associated with improvements in MTC in participants 3 and 4, and this provided descriptive information on the response pattern when both modalities were delivered from the outset.

The tDCS was applied in a bilateral montage, with the anode of the tDCS device (ActivaDose II, ActivaTek Inc., Salt Lake City, UT, USA) placed over the involved hemisphere and the cathode over the unaffected hemisphere. The tDCS device was set to 1 mA for 60 min during gait training, delivered via a pair of sponge electrodes moistened with 0.9% NaCl solution. The exact electrode placement locations were based on a 20-point electrode system, in which we selected two points targeting the motor cortex region corresponding to the left lower limb. Treatments were performed twice weekly over the 8 weeks.

The FES was administered to the tibialis anterior muscle of the impaired lower extremity with one electrode over the common peroneal nerve at the head of the fibula and the other over a motor point in the middle of the muscle belly of the tibialis anterior muscle. The frequency of the FES device (Chattanooga Continuum, DOJ Global, Vista, CA, USA) was set




Figure 2. Plot of the toe clearance for participants 1 to 4 (baseline) using the tip virtual marker or digit 5 for participant 1, who was barefoot. The black line represents the mean of the toe clearance pattern from a sample of 10 gait trials of data, out of the 25 collected for each participant. The toe clearance graphs were normalized to 100% of the swing phase.

to 35–50 pulses per second (pps), and the pulse duration was 200–300 microseconds, using a symmetrical biphasic current. The parameters were set to produce a visible and functional muscle contraction appropriate for each participant. The heel switch was positioned on the participant's heel or was adjusted anteriorly to the forefoot region for those participants who made initial contact at the forefoot. The FES was administered for the duration of the gait training (60 min), and its intensity was periodically adjusted to reduce accommodation to the stimulation.

The gait training consisted of treadmill training with forward and backward ambulation, with speed progression as appropriate; ambulation over obstacles; ramp ambulation forward and backward; and stair ambulation up and down. In each condition, cues were to increase toe clearance on the affected limb and achieve heel strike at initial contact. Vitals were collected at the start and end of each session, and heart rate was measured at the end of each activity, along with the Rating of

Perceived Exertion (RPE), to determine whether the participant was working at a higher intensity than baseline.

Follow-up and outcomes

Participant 1

Participant 1 ambulated with an inverted foot in the swing phase of gait, and the fifth digit was consistently the lowest point. With this gait pattern, there is no MTC event in the mid-swing phase of the gait cycle [52]. That is, after the initial peak after toe-off, the local minimum that typically occurs in mid-swing is no longer present. In fact, the foot was lifted to a maximum point in the mid-swing phase of the gait cycle before being lowered to the floor at initial contact (Fig. 2). At baseline, the clearance was 1.68 ± 0.59 cm; at mid-test, 1.44 ± 0.67 cm; and at post-test,

Table 2. Minimum or Maximum Toe Clearance and Joint Angle Data at Minimum Toe Clearance for All Four Participants Across All Three Testing Periods

Subject	MTC/ MAX L1 (cm) SD	MTC/MAX L2 (cm) SD	MTC/ MAX M1 (cm) SD	MTC/ MAX M2 (cm) SD	MTC/ MAX tip (cm) SD	Mean of lowest MTC val- ues across trials (cm) SD	Percentage of non-MTC for lowest MTC/MAX trials (%)	Ankle joint angle at lowest MTC/ MAX (°) SD	Knee joint angle at lowest MTC/MAX (°) SD	Hip joint angle at lowest MTC/ MAX (°) SD	Stance hip joint angle at lowest MTC/MAX (°) SD
Baseline											
1	1.68 (0.59)	Non-MTC	Non-MTC	Non-MTC	Non-MTC	1.68 (0.59)	100	-14.72 (1.54)	-28.84 (2.34)	22.75 (1.99)	-6.02 (1.38)
2	-0.26 (0.22)	0.47 (0.43)	Non-MTC	-0.57 (0.28)	Non-MTC	-0.36 (0.63)	14	5.73 (1.35)	-23.15 (1.31)	20.17 (2.25)	5.91 (1.22)
3	0.48 (0.56)	1.86 (0.69)	0.78 (0.060)	1.68 (0.59)	0.04 (0.68)	0.05 (0.67)	1.8	-12.15 (5.51)	-29.24 (3.49)	5.91 (2.36)	-6.80 (1.31)
4	Non-MTC	10.52 (1.68)	Non-MTC	Non-MTC	Non-MTC	10.52 (1.68)	100	-14.34 (1.76)	-19.95 (3.06)	31.45 (2.14)	-1.67 (3.88)
Mid-test (week 4)											
1	1.44 (0.67)	Non-MTC	Non-MTC	Non-MTC	Non-MTC	1.44 (0.67)	100	-14.51 (1.60)	-27.83 (2.23)	20.61 (1.60)	-7.00 (1.67)
2	0.13 (0.66)	1.56 (0.85)	0.07 (0.64)	0.29 (0.62)	-0.25 (0.58)	0.21 (1.04)	46.3	0.65 (2.25)	-51.98 (6.67)	26.07 (4.53)	2.38 (2.83)
3	1.09 (0.70)	1.35 (0.78)	0.67 (0.69)	1.92 (0.70)	1.39 (0.71)	0.68 (0.69)	1.4	-9.88 (4.86)	-28.41 (4.11)	7.94 (2.77)	-3.56 (1.84)
4	Non-MTC	8.30 (1.47)	Non-MTC	Non-MTC	Non-MTC	8.30 (1.47)	100	-16.96 (1.60)	-16.44 (1.90)	25.36 (2.02)	-2.12 (0.96)
Post-test (week 8)											
1	1.84 (0.68)	NON-MTC	Non-MTC	Non-MTC	Non-MTC	1.84 (0.68)	100	-11.42 (1.44)	-27.97 (2.10)	22.39 (2.42)	-0.95 (2.38)
2	0.21 (0.57)	1.42 (0.68)	-0.11 (0.56)	0.11 (0.53)	-0.55 (0.47)	0.12 (0.91)	59.4	0.07 (2.18)	-48.41 (5.80)	26.12 (4.46)	-2.92 (3.48)
3	0.77 (0.77)	1.47 (0.72)	0.98 (0.78)	1.54 (0.73)	0.89 (0.87)	0.82 (0.88)	1.3	-11.38 (6.23)	-29.41 (4.48)	7.81 (2.99)	-5.31 (1.08)
4	Non-MTC	8.65 (1.42)	Non-MTC	Non-MTC	Non-MTC	8.65 (1.42)	100	-14.55 (2.21)	-12.39 (2.24)	20.33 (2.12)	-6.33 (1.38)

Only the point with the lowest mean value is reported when all toe clearances are maximums, and other points are reported as non-MTC. Negative joint angles at the ankle = plantar-flexion; knee = flexion; swing hip = extension; and stance hip = abduction. SD: standard deviation; non-MTC: when the toe clearance graph does not have a minimum in the mid-swing phase of the gait cycle; NA: not applicable.




Figure 3. Plot of change in minimal toe clearance subjects 1–4 from baseline through mid-test point to post test.

1.84 ± 0.68 cm (Table 2 and Fig. 3). The average ankle joint angle at this maximum at baseline and the midpoint was -14.72° (SD: 1.54°) and -14.51° (SD: 1.60°), respectively. The ankle joint angle at post-test was -11.42° (SD: 1.44°) during the post-test period, including both tDCS and FES. No improvements were noted in any functional or gait measures (Table 3).

Participant 2

The lowest of the five digitized points that characterized the

front of the foot was used to define MTC for each trial. The lowest point from each of the 25 trials was then averaged to determine the mean MTC. The average of these lowest points was -0.36 cm (SD: 0.63 cm) at baseline, 0.21 ± 1.04 cm at mid-test, and 0.12 ± 0.9 cm at post-test (Table 2 and Fig. 3). The tip of the shoe had the lowest average value among the five digitized points in both mid-test and post-test periods, with 100% of trials resulting in non-MTC events at baseline. The average ankle joint angle at the lowest point on the front of the shoe was 5.73° (SD: 1.35°), 0.65° (SD: 2.25°) at mid-test and 0.07° (SD: 2.18°) at post-test. It was also note-

Table 3. Functional Outcome and Gait Measures

Subject	FGA	Walk-12	Stroke Impact Scale version 3			ABC scale	Gait speed (m/s) SD	Step length (m) SD	
			Mobility	Participation	Perceived recovery			Left	Right
Baseline									
1	17	60.42	86.1	62.5	75	73.1	0.30 (0.04)	0.28 (0.05)	0.14 (0.05)
2	11	47.92	80.6	68.8	50	65.6	0.75 (0.04)	0.57 (0.03)	0.45 (0.03)
3	24	10.42	**	**	70	95	0.74 (0.05)	0.57 (0.03)	0.57 (0.03)
4	10	31.25	83.3	50	40	34.5	0.18 (0.02)	0.13 (0.02)	0.27 (0.02)
Mid-test (week 4)									
1	16	58.33	86.1	78.1	65	68.1	0.33 (0.04)	0.29 (0.04)	0.18 (0.05)
2	15	29.17	94.4	96.9	55	69.5	0.76 (0.04)	0.59 (0.04)	0.49 (0.04)
3	19	52.08	77.8	34.4	70	76.9	0.67 (0.05)	0.55 (0.03)	0.52 (0.03)
4	11	81.25	66.7	56.3	80	56.3	0.21 (0.02)	0.15 (0.03)	0.30 (0.03)
Post-test (week 8)									
1	15	64.58	80.6	71.9	75	68.8	0.30 (0.05)	0.30 (0.06)	0.12 (0.05)
2	17	10.42	94.4	96.9	**	81.3	0.76 (0.05)	0.57 (0.04)	0.50 (0.03)
3	24	45.83	88.9	37.5	75	85	0.73 (0.04)	0.62 (0.03)	0.54 (0.03)
4	13	56.25	72.2	28.1	35	50	0.26 (0.02)	0.17 (0.03)	0.34 (0.02)

**Missing data. Walk-12 formula = Transformed Walk-12 score = $[(\text{Raw Walk-12 score} - 12)/48] \times 100$. Stroke Impact Scale subdomains $[(\text{Mean item score} - 1)/4] \times 100$. FGA: functional gait assessment; ABC scale: Activities-Specific Balance Confidence Scale.

worthy that knee flexion (baseline -23.15° (SD: 1.31°); post-test -48.41° (SD: 5.80°)), hip flexion (baseline 20.17° (SD: 2.25°); post-test 26.12° (SD: 4.46°), and hip abduction (baseline 5.91° (SD: 1.22°); post-test -2.92° (SD: 3.48°)) increased between baseline and post-test. Between baseline and post-test periods, there was a 6-point improvement in the FGA, a 37.5% reduction in perception of disability on the Walk-12, and a 28.1-point increase in the participation subscale of the stroke impact scale.

Participant 3

No single virtual point on the shoe was consistently the lowest point, on average, across all test periods. At baseline, the point at the shoe tip had the lowest average value of 0.05 ± 0.67 cm. At the mid-test and post-test periods, the lowest points were on the medial aspect of the shoe (M1) at 0.68 ± 0.69 cm and on the shoe's lateral aspect (L1) at 0.82 ± 0.88 cm, respectively. The percentages of non-MTC events at the lowest points in the baseline, mid-test, and post-test periods were 2%, 1.4%, and 5%, respectively. The ankle joint angles at these points at baseline, mid-test, and post-test periods, respectively, were -12.15° (SD: 5.51°), -9.88° (SD: 4.86°), and -11.38° (SD: 6.23°). Concurrently, hip flexion increased from baseline 5.91° (SD: 2.36°) to 7.94° (SD: 2.77°) at mid-test, and remained relatively consistent at post-test 7.81° (SD: 2.99°). The swing phase toe clearance pattern resembled the typical pattern found in healthy adults, with the characteristic two maxima surrounding the minimum of MTC (Fig. 2) [28, 53–55]. However, MTC tended to occur earlier in the swing phase, and the large maximum at the end was not associated with heel strike but occurred before foot-flat. Additionally, there was an increase in the Walk-12 score by 35.41 points and a reduction in the ABC scale of 10 points between baseline and post-test periods (Table 3).

Participant 4

The gait pattern did not produce a minimum at MTC. A point on the shoe's lateral aspect (L2) was consistently the lowest at the maximum. The clearance amounts at the baseline, mid-test, and post-test phases were 10.52 ± 1.68 cm, 8.30 ± 1.47 cm, and 8.65 ± 1.43 cm, respectively (Table 2 and Fig. 3). The average ankle joint angle at this maximum at baseline, mid-test, and post-test phases, respectively, was -14.34° (SD: 1.76°), -16.96° (SD: 1.60°), and -14.55° (SD: 2.21°) (Table 2). These ankle changes were associated with concurrent increased extension in knee (baseline -19.95° (SD: 3.06°); mid-test -16.44° (SD: 1.90°); post-test -12.39° (SD: 2.24°)) and hip (baseline 31.45° (SD: 2.14°); mid-test 25.36° (SD: 2.02°); post-test 20.33° (SD: 2.12°)) movements, and stance hip adduction (baseline -1.67° (SD: 3.88°); mid-test -2.12° (SD: 0.96°); post-test -6.33° (SD: 1.38°)). Between the baseline and post-test periods, the Walk-12 score increased by 25 points, and the mobility and participation domains of the Stroke Impact Scale decreased by 11.1 and 21.9 points, respectively (Table 3).

Discussion

In this case series, we evaluated whether combining FES and tDCS within a PTT session would increase toe clearance at MTC in a cohort of PPS. This increase in toe clearance at MTC was hypothesized to be associated with improved ankle dorsiflexion, potentially indicating improved tibialis anterior (TA) activation. However, the observed changes in MTC could not be interpreted as reflecting ankle dorsiflexion alone. MTC is an endpoint measure influenced by the coordinated motion of multiple joints, and the present kinematic data suggest that participants may have used different multi-joint strategies to modify toe clearance. For example, ankle position did not consistently explain the direction of change in MTC. In some participants, greater plantarflexion would be expected to reduce toe clearance, whereas concurrent changes in hip or knee flexion appeared more consistent with the observed MTC response. Therefore, the hypothesis that increased MTC primarily reflects improved ankle dorsiflexion or enhanced dorsiflexor control is not fully supported by the present data. Further, we did not identify consistent improvements in toe clearance across all participants. This inconsistency was paralleled by the clinical measures, which also showed inconsistent improvements.

Participants 1 and 4 adopted toe clearance strategies that resulted in what Santhiranayagam et al referred to as non-MTC events—or the non-occurrence of a MTC event [52]. The literature provides evidence that non-MTC events occur more frequently in individuals at greater risk of falling [52, 56–59]. Therefore, these participants may employ this strategy to reduce their fall risk. For participant 1, the lateral aspect of her foot (fifth MET) was consistently the lowest point due to ankle inversion during the swing phase. With this non-MTC strategy, the toe clearance curves peaked in the midswing phase, where MTC typically occurred [6, 27, 60]. The toe clearance values observed at this peak (baseline: $1.68 \text{ cm} \pm 0.59$; mid-test: $1.44 \text{ cm} \pm 0.67$ cm, and post-test: 1.84 ± 0.68 cm; Table 2) were comparable to the mean MTC values reported in the literature for both healthy young and older adults, which typically range from 1 to 3 cm [6, 27]. Also, there was slightly more dorsiflexion (post-test: $-11.42 \pm 1.44^\circ$) at the post-test with the inclusion of both tDCS and FES than at the mid-test ($-14.51 \pm 1.60^\circ$), where only tDCS was included. In fact, at mid-test, ankle dorsiflexion remained relatively unchanged from baseline ($-14.72 \pm 1.54^\circ$). These changes in toe clearance were not reflected in functional measures, as they were not accompanied by substantive changes in gait metrics or the improvement in the participant's perceptions of their gait ability. It is possible that these changes in MTC may not be reflected in broader functional measures, as MTC may be a specific variable of the swing phase that may have implications for trip-related falls.

For participant 4, who received tDCS, FES, and PTT beginning at baseline, the maximum non-MTC event count was much higher than for participant 1. This higher clearance may be associated with a greater metabolic cost, but this remains unclear, as increasing MTC by 4 cm, which is less than the 5 to 7 cm increase observed for this participant, did not significantly affect dorsiflexion moments and muscle forces [61].

The maximum in the toe clearance curve decreased between baseline (10.52 ± 1.68 cm) and post-test (8.65 ± 1.42 cm). Ankle position did not consistently explain the observed changes in MTC. For example, ankle plantarflexion increased at mid-test relative to baseline, which would be expected to reduce toe clearance and was consistent with the lower MTC observed at that time point. However, ankle position returned toward baseline at post-test while toe clearance remained lower, suggesting that ankle motion alone did not account for the MTC response. The concurrent increases in knee and hip extension suggest that proximal joint motion may have contributed to the reduced toe clearance in this participant. These changes were not associated with improvements in functional measures, reiterating the possibility that changes in MTC may not translate to consistent functional improvements. Interestingly, neither of these participants (participants 1 and 4) who used this non-MTC strategy achieved isolated active dorsiflexion.

Participants 2 and 3 achieved active dorsiflexion, although weak (grade 2 manual muscle test score), and had MTC events. Participant 2, who began with FES alone, noted an increase in the mean lowest MTC amount from -0.36 ± 0.63 cm at baseline to 0.21 ± 1.04 cm at mid-test. However, with the addition of tDCS at mid-test, there was a slight reduction in the average lowest MTC at post-test to 0.12 ± 0.90 cm. Further, the slight increase in toe clearance amount from baseline to mid-test was not accompanied by an increase in dorsiflexion as expected [24, 47, 51, 56, 62, 63] but a decrease from $5.73 \pm 1.35^\circ$ to 0.65° (2.25°) at the lowest average point. The lower toe clearance amount at MTC at post-test, relative to mid-test, corresponded with slightly less dorsiflexion ($0.07 \pm 2.18^\circ$). A combination of increased hip flexion of the swing limb and hip abduction of the stance limb may have offset the lower dorsiflexion, accounting for the higher clearances at mid-test. Therefore, these findings suggest that higher toe clearance should not be assumed to result solely from increased ankle dorsiflexion. Additionally, there were clinically meaningful improvements in the FGA from baseline to post-test (a 6-point increase) and a 37% reduction in their perceived walking limitations on the Walk-12, shifting their perception from moderate to mild. These findings may reflect concurrent functional improvements in this patient unrelated to changes in MTC, as functional measures may capture broader domains, including balance, strength, endurance, and overall mobility, whereas MTC may be a specific swing-phase variable. It is unclear from this study why improvements in MTC in this particular patient were associated with concurrent functional improvements, and this should be explored in other studies.

For participant 3, the improvement in the average lowest toe clearance at MTC was more dramatic, increasing from 0.05 ± 0.67 cm at baseline to 0.68 ± 0.69 cm at mid-test, then to 0.82 ± 0.88 cm at post-test. However, the expectation that this improvement in the average toe clearance amount at MTC would be consistently accompanied by increased dorsiflexion was not realized [24, 47, 51, 56, 62, 63]. "In fact, there was an increase in relative dorsiflexion between baseline and mid-test periods, going from -12.15° (SD: 5.51°) to -9.88° (SD: 4.86°) at mid-test, as expected, but there was relatively more plantarflexion at post-test ($-11.38 \pm 6.23^\circ$) than at mid-test. Because MTC is an endpoint measure that can be influenced

by the individual or coordinated kinematics of multiple lower-limb joints, the present data suggest that the slightly greater hip flexion at mid-test and post-test relative to baseline may have contributed to the increases in MTC for participant 3. However, the authors cannot definitively determine whether the observed changes in MTC in participant 3 and the other three participants were primarily related to ankle dorsiflexion or to changes in other lower-limb joints [51]. Therefore, it remains possible that different participants may use distinct multi-joint strategies to modify toe clearance, including proximal compensations involving the hip, knee, and pelvis. These changes, while notable for MTC, did not translate into improvements on either the FGA or the Walk-12 scales, and the ABC scale did exceed the minimal detectable change. These findings suggest that improvements in MTC may not consistently correspond with measurable functional gains or improved perceptions of walking limitations in this population. However, because MTC is more directly related to foot clearance and may reflect trip risk, changes in MTC may not be fully captured by broader functional outcome measures.

Interestingly, for participants 2 and 3, non-MTC events were frequent on the part of the shoe, with the lowest average clearance when toe clearances were small. The mean increase in toe clearance at MTC for these participants between baseline and post-test was $((0.12 - (-0.36)) + (0.82 - 0.05))/2 = (0.48 + 0.77)/2 = 0.63$ cm. This mean increase exceeds the previously reported error estimate of ± 0.2 cm for virtual point-based foot clearance calculations [64]. At the individual level, both participants' changes were also beyond this measurement error range. These findings suggest that the observed increases in foot clearance were likely detectable changes rather than measurement variability alone. However, because a minimal clinically important difference has not been established for MTC, and because this study did not directly measure trip or fall incidence, these changes cannot be interpreted as definitive evidence of reduced fall risk. Further research is needed to determine whether changes of this magnitude are clinically meaningful. It was unclear from these participants whether including tDCS was beneficial, as participant 2 showed improvement with FES alone, and although participant 3's improvement was larger, there was no FES-only control condition for participant 3. Therefore, it is impossible to determine whether tDCS provided additional benefits over FES.

Interestingly, all participants without active dorsiflexion produced all non-MTC events. In contrast, participants with MTC events tended to produce non-MTC events more frequently in the front foot areas closest to the ground. For example, for participant 2, the shoe tip was closest to the ground during the mid-test and post-test periods. Consequently, with more non-MTC events, this area contributed less to the lowest average toe clearance at MTC, thereby increasing the lowest average toe clearance because these were no longer the minimum events to be counted. Based on this analysis, using a single point at the tip of the shoe or a single marker, a common practice utilized in MTC studies [28, 61, 65–68], would not be sufficient to characterize the complexity displayed by these participants with chronic stroke in achieving toe clearance.

The pattern of change in the clinical outcome measures was also unclear. For participants 1 and 4, only participant 4

noted clinically significant improvements in the functional measures on the Walk-12 [69] and the mobility [70] and participation [71] subdomains of the Stroke Impact Scale, despite not experiencing changes in toe clearance. For participants 2 and 3, who noted improvements in toe clearance at MTC, participant 2 showed significant improvements on the functional measures of the FGA [72], Walk-12 [69], and the participation subscale of the Stroke Impact Scale [71]. For participant 3, there was an unanticipated worsening in perceived disability, as evidenced by an increase in the Walk-12 score, and the ABC scale did not achieve a clinically meaningful improvement despite improved toe clearance [73].

There were limitations associated with this study. First, participant 3 wore different shoes during the mid-test session, and the shoe type has been shown to affect MTC magnitude [74, 75]. However, the identical shoe to the baseline was used at the post-test. Second, electromyographic data were not collected from the tibialis anterior muscle, so we cannot infer whether any of the improvements were due to improved tibialis anterior activation. Furthermore, any of the six lower-limb joints may increase toe clearance at MTC, further confounding the question of whether increases in toe clearance in this present study were related to increased dorsiflexion resulting from improved TA activation. Third, negative values were recorded in this study, which is an artifact introduced by measurement error but is not atypical in MTC studies [47, 64, 76, 77]. Fourth, we did not perform an inter-rater reliability assessment of the raters for the clinical outcomes. Fifth, the heterogeneous intervention structure should be interpreted as an exploratory case series design rather than a comparative efficacy design. Specifically, the design permits examination of within participant response patterns before and after the addition of a second modality, but it does not isolate the independent effect of tDCS, FES, or physical therapy training, as there was no independent comparator condition. Therefore, improvements observed during the combined treatment phase may reflect the added modality, continued response to the initial modality, cumulative treatment exposure, repeated task practice, physical therapy training, or an interaction among these components. Accordingly, the findings should be interpreted as hypothesis generating evidence regarding whether combined tDCS and FES may provide added benefit in individual cases, rather than definitive evidence that the combined intervention is superior to either modality alone.

Learning points

We noted an average MTC increase of 0.63 cm in PPS who achieved active dorsiflexion at the outset of treatment, but no improvement in those who did not. While the increase in toe clearance exceeded the measurement error, it cannot be interpreted as clinically significant, as neither a minimal clinically important difference nor another clinically meaningful threshold has been established. We anticipated a correlation between MTC improvements and ankle dorsiflexion, but results were inconsistent and often concurrent with changes in proximal joints. Furthermore, since tibialis anterior muscle activation

was not measured, its role remains unclear. The MTC improvements were not consistently associated with functional gains or patient-reported walking limitations, suggesting that MTC may indicate trip risk more than broader functional changes. Lastly, because we did not isolate the effects of tDCS, FES, or PTT, these findings are hypothesis generating rather than definitive proof of their combined superiority.

Acknowledgments

The authors would like to acknowledge the support of Capstone students Annie Sokolski and Elisabeth LoCierito. Portions of this project were previously presented at the 2025 American Physical Therapy Association Annual Conference, Houston, TX, and the 2024 Clinical Movement Analysis Society Annual Conference, Georgia Institute of Technology, Atlanta, GA.

Financial Disclosure

The study was supported by Milton Lev Memorial Faculty Research Fund, Saint Joseph's University internal funds grant Spring 2024-2025:(5K).

Conflict of Interest

None to declare.

Informed Consent

Informed consent was obtained from the subjects prior to participation in the study.

Author Contributions

Gregory Thielman oversaw subject training and test collection/analysis of the standard outcome measures, while Sylvester Carter collected and analyzed the kinematic data. Both authors were involved in all aspects of the manuscript preparation, writing, and editing.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Abbreviations

ABC scale: Activity-specific Based Confidence scale; AFOs: ankle-foot orthoses; ASIS: anterior superior iliac spines; CAST: calibrated anatomical system technique; CVA: cer-

ebrovascular accident; FES: functional electrical stimulation; MET: fifth metatarsal; MTC: minimum toe clearance; pps: pulses per second; PPS: persons post-stroke; PTT: physical therapy training; RPE: Rating of Perceived Exertion; TA: tibi-
alis anterior; tDCS: transcranial direct current stimulation

References

1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Aro-
ra P, Avery CL, Baker-Smith CM, et al. Heart disease and
stroke statistics-2023 update: a report from the American
Heart Association. *Circulation*. 2023;147(8):e93-e621.
[doi pubmed](#)
2. Peishun C, Haiwang Z, Taotao L, Hongli G, Yu M, Wan-
rong Z. Changes in Gait Characteristics of Stroke Patients
with Foot Drop after the Combination Treatment of Foot
Drop Stimulator and Moving Treadmill Training. *Neural
Plast*. 2021;2021:9480957. [doi pubmed](#)
3. O'Dell MW, Dunning K, Kluding P, Wu SS, Feld J, Gino-
sian J, McBride K. Response and prediction of improve-
ment in gait speed from functional electrical stimulation in
persons with poststroke drop foot. *PM R*. 2014;6(7):587-
601; quiz 601. [doi pubmed](#)
4. Nolan KJ, Savalia KK, Lequerica AH, Elovic EP. Objec-
tive assessment of functional ambulation in adults with
hemiplegia using ankle foot orthotics after stroke. *PM R*.
2009;1(6):524-529. [doi pubmed](#)
5. Nolan KJ, Yarossi M. Weight transfer analysis in adults
with hemiplegia using ankle foot orthosis. *Prosthet Or-
thot Int*. 2011;35(1):45-53. [doi pubmed](#)
6. Al Bochi A, Delfi G, Dutta T. A scoping review on mini-
mum foot clearance: an exploration of level-ground clear-
ance in individuals with abnormal gait. *Int J Environ Res
Public Health*. 2021;18(19). [doi pubmed](#)
7. Maki BE. Gait changes in older adults: predictors of falls
or indicators of fear. *J Am Geriatr Soc*. 1997;45(3):313-
320. [doi pubmed](#)
8. Berg WP, Alessio HM, Mills EM, Tong C. Circumstances
and consequences of falls in independent community-
dwelling older adults. *Age Ageing*. 1997;26(4):261-268.
[doi pubmed](#)
9. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim
SB, Arie TH, Fentem PH, et al. Falls by elderly people
at home: prevalence and associated factors. *Age Ageing*.
1988;17(6):365-372. [doi pubmed](#)
10. Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls
in a community-based prospective study of people 70
years and older. *J Gerontol*. 1989;44(4):M112-117. [doi
pubmed](#)
11. Hausdorff JM, Rios DA, Edelberg HK. Gait vari-
ability and fall risk in community-living older adults:
a 1-year prospective study. *Arch Phys Med Rehabil*.
2001;82(8):1050-1056. [doi pubmed](#)
12. Hornbrook MC, Stevens VJ, Wingfield DJ, Hollis JF,
Greenlick MR, Ory MG. Preventing falls among commu-
nity-dwelling older persons: results from a randomized
trial. *Gerontologist*. 1994;34(1):16-23. [doi pubmed](#)
13. Prudham D, Evans JG. Factors associated with falls in the
elderly: a community study. *Age Ageing*. 1981;10(3):141-
146. [doi pubmed](#)
14. Sterling DA, O'Connor JA, Bonadies J. Geriatric falls: in-
jury severity is high and disproportionate to mechanism.
J Trauma. 2001;50(1):116-119. [doi pubmed](#)
15. Mackintosh SF, Goldie P, Hill K. Falls incidence and fac-
tors associated with falling in older, community-dwell-
ing, chronic stroke survivors (> 1 year after stroke) and
matched controls. *Aging Clin Exp Res*. 2005;17(2):74-
81. [doi pubmed](#)
16. Batchelor FA, Mackintosh SF, Said CM, Hill KD. Falls
after stroke. *Int J Stroke*. 2012;7(6):482-490. [doi pubmed](#)
17. Dunning K, O'Dell MW, Kluding P, McBride K. Peroneal
stimulation for foot drop after stroke: a systematic review.
Am J Phys Med Rehabil. 2015;94(8):649-664. [doi pub-
med](#)
18. Schmid AA, Yaggi HK, Burrus N, McClain V, Austin C,
Ferguson J, Fragoso C, et al. Circumstances and conse-
quences of falls among people with chronic stroke. *J Re-
habil Res Dev*. 2013;50(9):1277-1286. [doi pubmed](#)
19. Begg R, Galea MP, James L, Sparrow WAT, Levinger
P, Khan F, Said CM. Real-time foot clearance biofeed-
back to assist gait rehabilitation following stroke: a ran-
domized controlled trial protocol. *Trials*. 2019;20(1):317.
[doi pubmed](#)
20. Nagano H, Said CM, James L, Begg RK. Feasibility of us-
ing foot-ground clearance biofeedback training in tread-
mill walking for post-stroke gait rehabilitation. *Brain Sci*.
2020;10(12). [doi pubmed](#)
21. Begg RK, Tirosh O, Said CM, Sparrow WA, Steinberg N,
Levinger P, Galea MP. Gait training with real-time aug-
mented toe-ground clearance information decreases trip-
ping risk in older adults and a person with chronic stroke.
Front Hum Neurosci. 2014;8:243. [doi pubmed](#)
22. Balaban B, Tok F. Gait disturbances in patients with
stroke. *PM R*. 2014;6(7):635-642. [doi pubmed](#)
23. Chen G, Patten C, Kothari DH, Zajac FE. Gait differenc-
es between individuals with post-stroke hemiparesis and
non-disabled controls at matched speeds. *Gait Posture*.
2005;22(1):51-56. [doi pubmed](#)
24. Moosabhoy MA, Gard SA. Methodology for determin-
ing the sensitivity of swing leg toe clearance and leg
length to swing leg joint angles during gait. *Gait Posture*.
2006;24(4):493-501. [doi pubmed](#)
25. Burpee JL, Lewek MD. Biomechanical gait character-
istics of naturally occurring unsuccessful foot clearance
during swing in individuals with chronic stroke. *Clin Bio-
mech (Bristol)*. 2015;30(10):1102-1107. [doi pubmed](#)
26. Little VL, McGuirk TE, Patten C. Impaired limb short-
ening following stroke: what's in a name? *PLoS One*.
2014;9(10):e110140. [doi pubmed](#)
27. Barrett RS, Mills PM, Begg RK. A systematic review of
the effect of ageing and falls history on minimum foot
clearance characteristics during level walking. *Gait Pos-
ture*. 2010;32(4):429-435. [doi pubmed](#)
28. Begg R, Best R, Dell'Oro L, Taylor S. Minimum foot
clearance during walking: strategies for the minimisation
of trip-related falls. *Gait Posture*. 2007;25(2):191-198.
[doi pubmed](#)

29. Hyndman D, Ashburn A, Stack E. Fall events among people with stroke living in the community: circumstances of falls and characteristics of fallers. *Arch Phys Med Rehabil.* 2002;83(2):165-170. [doi pubmed](#)
30. Osada Y, Kobayashi Y, Osuka T, Yamamoto S. How do individuals with subacute stroke nearly fall during forward walking? *Gait Posture.* 2025;120:98-103. [doi pubmed](#)
31. El-Osta B, Wilson R. Concepts in Foot Drop Management- Review of the Current Literature. *Acta Sci Orthop.* 2019;2(10):37-45 [doi](#)
32. Jaqueline da Cunha M, Rech KD, Salazar AP, Pagnus-sat AS. Functional electrical stimulation of the peroneal nerve improves post-stroke gait speed when combined with physiotherapy. A systematic review and meta-analysis. *Ann Phys Rehabil Med.* 2021;64(1):101388. [doi pubmed](#)
33. Kristensen MGH, Busk H, Wienecke T. Neuromuscular electrical stimulation improves activities of daily living post stroke: a systematic review and meta-analysis. *Arch Rehabil Res Clin Transl.* 2022;4(1):100167. [doi pubmed](#)
34. Milosevic M, Marquez-Chin C, Masani K, Hirata M, Nomura T, Popovic MR, Nakazawa K. Why brain-controlled neuroprosthetics matter: mechanisms underlying electrical stimulation of muscles and nerves in rehabilitation. *Biomed Eng Online.* 2020;19(1):81. [doi pubmed](#)
35. Denissen S, Staring W, Kunkel D, Pickering RM, Lennon S, Geurts AC, Weerdesteyn V, et al. Interventions for preventing falls in people after stroke. *Cochrane Database Syst Rev.* 2019;10(10):CD008728. [doi pubmed](#)
36. Reed T, Cohen Kadosh R. Transcranial electrical stimulation (tES) mechanisms and its effects on cortical excitability and connectivity. *J Inherit Metab Dis.* 2018;41(6):1123-1130. [doi pubmed](#)
37. Stoykov ME, Madhavan S. Motor priming in neurorehabilitation. *J Neurol Phys Ther.* 2015;39(1):33-42. [doi pubmed](#)
38. Andrade SM, Ferreira JJA, Rufino TS, Medeiros G, Brito JD, da Silva MA, Moreira RN. Effects of different montages of transcranial direct current stimulation on the risk of falls and lower limb function after stroke. *Neurol Res.* 2017;39(12):1037-1043. [doi pubmed](#)
39. Chow AD, Shin J, Wang H, Kellawan JM, Pereira HM. Influence of transcranial direct current stimulation dosage and associated therapy on motor recovery post-stroke: a systematic review and meta-analysis. *Front Aging Neurosci.* 2022;14:821915. [doi pubmed](#)
40. Navarro-Lopez V, Molina-Rueda F, Jimenez-Jimenez S, Alguacil-Diego IM, Carratala-Tejada M. Effects of transcranial direct current stimulation combined with physiotherapy on gait pattern, balance, and functionality in stroke patients. A systematic review. *Diagnostics (Basel).* 2021;11(4). [doi pubmed](#)
41. Jeffery DT, Norton JA, Roy FD, Gorassini MA. Effects of transcranial direct current stimulation on the excitability of the leg motor cortex. *Exp Brain Res.* 2007;182(2):281-287. [doi pubmed](#)
42. Shaheiwola N, Zhang B, Jia J, Zhang D. Using tDCS as an add-on treatment prior to FES therapy in improving upper limb function in severe chronic stroke patients: a randomized controlled study. *Front Hum Neurosci.* 2018;12:233. [doi pubmed](#)
43. Fruhauf AMA, Politti F, Dal Corso S, Costa GC, Teodosio ADC, Silva SM, Correa JCF, et al. Immediate effect of transcranial direct current stimulation combined with functional electrical stimulation on activity of the tibialis anterior muscle and balance of individuals with hemiparesis stemming from a stroke. *J Phys Ther Sci.* 2017;29(12):2138-2146. [doi pubmed](#)
44. Cappozzo A, Cappello A, Della Croce U, Pensalfini F. Surface-marker cluster design criteria for 3-D bone movement reconstruction. *IEEE Trans Biomed Eng.* 1997;44(12):1165-1174. [doi pubmed](#)
45. Cappozzo A, Catani F, Croce UD, Leardini A. Position and orientation in space of bones during movement: anatomical frame definition and determination. *Clin Biomech (Bristol).* 1995;10(4):171-178. [doi pubmed](#)
46. Zeni JA, Jr., Richards JG, Higginson JS. Two simple methods for determining gait events during treadmill and overground walking using kinematic data. *Gait Posture.* 2008;27(4):710-714. [doi pubmed](#)
47. Carter SC, Batavia MZ, Gutierrez GM, Capezuti EA. Joint movements associated with minimum toe clearance variability in older adults during level overground walking. *Gait Posture.* 2020;75:14-21. [doi pubmed](#)
48. Loverro KL, Mueske NM, Hamel KA. Location of minimum foot clearance on the shoe and with respect to the obstacle changes with locomotor task. *J Biomech.* 2013;46(11):1842-1850. [doi pubmed](#)
49. Schulz BW. Healthy younger and older adults control foot placement to avoid small obstacles during gait primarily by modulating step width. *J Neuroeng Rehabil.* 2012;9:69. [doi pubmed](#)
50. Schulz BW, Lloyd JD, Lee WE, 3rd. The effects of everyday concurrent tasks on overground minimum toe clearance and gait parameters. *Gait Posture.* 2010;32(1):18-22. [doi pubmed](#)
51. Winter DA. Foot trajectory in human gait: a precise and multifactorial motor control task. *Phys Ther.* 1992;72(1):45-53; discussion 54-46. [doi pubmed](#)
52. Santhirayanagam BK, Sparrow WA, Lai DTH, Begg RK. Non-MTC gait cycles: an adaptive toe trajectory control strategy in older adults. *Gait Posture.* 2017;53:73-79. [doi pubmed](#)
53. Begg RK, Palaniswami M, Owen B. Support vector machines for automated gait classification. *IEEE Trans Biomed Eng.* 2005;52(5):828-838. [doi pubmed](#)
54. Hassan R, Begg R, Taylor S. Fuzzy logic-based recognition of gait changes due to trip-related falls. *Conf Proc IEEE Eng Med Biol Soc.* 2005;2005:4970-4973. [doi pubmed](#)
55. Nagano H, Begg RK, Sparrow WA, Taylor S. Ageing and limb dominance effects on foot-ground clearance during treadmill and overground walking. *Clin Biomech (Bristol).* 2011;26(9):962-968. [doi pubmed](#)
56. Little VL, McGuirk TE, Patten C. Slower than normal walking speeds involve a pattern shift in joint and temporal coordination contributions. *Exp Brain Res.*

- 2019;237(11):2973-2982. [doi pubmed](#)
57. Santhiranayagam BK, Lai DT, Sparrow WA, Begg RK. Minimum toe clearance events in divided attention treadmill walking in older and young adults: a cross-sectional study. *J Neuroeng Rehabil*. 2015;12:58. [doi pubmed](#)
 58. Sasaki K, Ooi T, Yokota A, Azuma T, Asano K, Yadaï G. The effects of cognitive tasks on the frequency of non-MTC gait cycle during walking in healthy older and young adults. *J Phys Ther Sci*. 2022;34(7):497-502. [doi pubmed](#)
 59. Schulz BW. Minimum toe clearance adaptations to floor surface irregularity and gait speed. *J Biomech*. 2011;44(7):1277-1284. [doi pubmed](#)
 60. Nagano H, Begg RK. Shoe-insole technology for injury prevention in walking. *Sensors (Basel)*. 2018;18(5). [doi pubmed](#)
 61. Bajelan S, Sparrow WAT, Begg R. The ankle dorsiflexion kinetics demand to increase swing phase foot-ground clearance: implications for assistive device design and energy demands. *J Neuroeng Rehabil*. 2024;21(1):105. [doi pubmed](#)
 62. Carter S, Saghaï A. An exploration of the effects of gait speed and joint movements on minimum toe clearance across the lifespan: a cross-sectional study. *J Appl Biomech*. 2025;41(4):323-332. [doi pubmed](#)
 63. Cui C, Muir B, Rietdyk S, Haddad J, van Emmerik R, Ambike S. Sensitivity of the toe height to multijoint angular changes in the lower limbs during unobstructed and obstructed gait. *J Appl Biomech*. 2021;37(3):224-232. [doi pubmed](#)
 64. Startzell JK, Cavanagh PR. A three-dimensional approach to the calculation of foot clearance during locomotion. *Hum Mov Sci*. 1999;18(5):603-611.
 65. de Freitas PB, Freitas S, Dias MS. Synergic control of the minimum toe clearance in young and older adults during foot swing on treadmill walking in different speeds. *Gait Posture*. 2024;111:150-155. [doi pubmed](#)
 66. Sengupta N, Begg R, Rao AS, Bajelan S, Said CM, Palaniswami M. Predicting improvement in biofeedback gait training using short-term spectral features from minimum foot clearance data. *Front Bioeng Biotechnol*. 2024;12:1417497. [doi pubmed](#)
 67. Pruyn K, Murray R, Gabert L, Lenzi T. Autonomous powered ankle exoskeleton improves foot clearance and knee hyperextension after stroke: a case study. *IEEE Trans Med Robot Bionics*. 2025;7(1):51-58. [doi pubmed](#)
 68. Dias MS, Freitas S, de Freitas PB. Multi-joint synergy in foot height stabilization across different running speeds: an uncontrolled manifold analysis. *Res Q Exerc Sport*. 2025;96(4):650-659. [doi pubmed](#)
 69. Motl RW, Learmonth YC, Pilutti LA, Dlugonski D, Klaren R. Validity of minimal clinically important difference values for the multiple sclerosis walking scale-12? *Eur Neurol*. 2014;71(3-4):196-202. [doi pubmed](#)
 70. Lin KC, Fu T, Wu CY, Wang YH, Liu JS, Hsieh CJ, Lin SF. Minimal detectable change and clinically important difference of the Stroke Impact Scale in stroke patients. *Neurorehabil Neural Repair*. 2010;24(5):486-492. [doi pubmed](#)
 71. Kao SC, Pai HC. Minimal clinically important differences and changes in stroke disease-specific quality of life in stroke survivors: a prospective cohort study. *Clin Nurs Res*. 2023;32(3):510-517. [doi pubmed](#)
 72. Lin JH, Hsu MJ, Hsu HW, Wu HC, Hsieh CL. Psychometric comparisons of 3 functional ambulation measures for patients with stroke. *Stroke*. 2010;41(9):2021-2025. [doi pubmed](#)
 73. Mestanza Mattos FG, Bowman T, Allera Longo C, Bocini S, Gennuso M, Marazzini F, Materazzi FG, et al. Establishing minimal clinically important difference of modified dynamic gait index in people with subacute stroke. *Top Stroke Rehabil*. 2025;32(6):640-644. [doi pubmed](#)
 74. Thies SB, Jones RK, Kenney LP, Howard D, Baker R. Effects of ramp negotiation, paving type and shoe sole geometry on toe clearance in young adults. *J Biomech*. 2011;44(15):2679-2684. [doi pubmed](#)
 75. Carter S. An exploration of the agreement, inter- and intra-rater reliability, and reproducibility of three common methods used to measure minimum toe clearance with optical motion capture systems under three shoe conditions. *Gait Posture*. 2024;113:534-542. [doi pubmed](#)
 76. Dingwell JB, Ulbrecht JS, Boch J, Becker MB, O'Gorman JT, Cavanagh PR. Neuropathic gait shows only trends towards increased variability of sagittal plane kinematics during treadmill locomotion. *Gait Posture*. 1999;10(1):21-29. [doi pubmed](#)
 77. Miller CA, Feiveson AH, Bloomberg JJ. Effects of speed and visual-target distance on toe trajectory during the swing phase of treadmill walking. *J Appl Biomech*. 2009;25(1):32-42. [doi pubmed](#)